Gapping up
In reaction to strong earnings/guidance:
- CLX +5.4%, MUFG +5%, ON +4.6%, ALXN +3.7%, MTSC +0.6%
M&A news:
- ULTI +18.5% (to be acquired by an investor group led by Hellman & Friedman in an all-cash transaction for $331.50/share after which Ultimate Software will operate privately) .
Other news:
- EOLS +19.7% (confirms FDA approval for Jeuveau prabotulinumtoxinA-xvfs for injection)
- HALO +9.2% (Halozyme Therapeutics & argenx (ARGX) announce global collaboration and license agreement)
- SENS +5.4% (announces extension of its distribution agreement with Roche (RHHBY) Diabetes Care)
- PZZA +4.5% (confirms $200 mln strategic investment from Starboard and appointment of three new directors to Papa John's Board; offers prelim Q4 results & early 2019 results)
- BMY +2.9% (Starboard plans to take stake in Bristol-Myers)
- PCG +2.3% (receives court approval of 'first day' motions to support normal business ops; obtains interim approval to access up to $1.5 billion in DIP financing)
- WDC +1.3% (continued strength)
Analyst comments:
- COP +9.2% (upgraded to Buy from Neutral at Goldman)
- ICPT +2.9% (upgraded to Strong Buy from Outperform at Raymond James)
- SNDR +2.1% (upgraded to Buy from Underperform at BofA/Merrill)
- ANGI +0.5% (initiated with a Buy at Goldman)